相关实验视频

Updated: Jun 12, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

向的细胞亡免疫调节器用于转移EGFR阳性固体瘤的治疗

Derrick Broka¹, Shoshana Klein², Alexei Shir^1,2

¹TargImmune Therapeutics, Basel 4057, Switzerland.

Proceedings of the National Academy of Sciences of the United States of America

|May 29, 2025

概括

向性亡性免疫调节剂 (TAIM) 提供了一种新的方法,通过诱导瘤细胞死亡和激活免疫反应来对抗EGFR过度表达的癌症. 这种纳米粒子平台TAR001在临床前模型中显示出延长生存和抑制瘤生长的前景.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
纳米医学是一种纳米医学.

背景情况:

异常的表皮生长因子受体 (EGFR) 信号驱动各种固体癌症,往往导致不良预后.
针对EGFR的治疗因瘤耐药性,异质性和免疫抑制性瘤微环境 (TME) 而面临限制.

研究的目的:

为了研究TAR001的多方面的作用模式,一种新型的向性亡性免疫调节器 (TAIM) 纳米粒子.
评估TAR001在诱导瘤细胞死亡和激活对EGFR过度表达癌症的抗瘤免疫力的有效性.

主要方法:

开发一个非病毒纳米粒子平台 (TAIM) 用于针对性地输送聚氨酸:聚氨酸 (polyIC).
在EGFR过度表达的癌症模型中评估TAR001的选择性,免疫反应诱导和TME调节.
在小鼠瘤模型中评估全身传递疗效.

主要成果:

TAR001对EGFR过度表达的癌症具有选择性,诱导细胞亡,细胞因子分泌和抗瘤免疫.
TAR001有效调节TME,招募和激活先天性和适应性免疫细胞.
在多个临床前模型中,系统性TAR001输送显著延长了生存时间,并抑制了瘤生长.

结论:

TAR001代表了一种创新的,安全的,多式治疗策略,用于转移EGFR阳性固体癌症.
这种方法通过同时诱导亡和免疫激活来克服瘤抵抗机制.
TAR001具有治疗转移性头,非小细胞肺癌,结直肠癌,癌和三阴性乳腺癌的潜力.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.免疫疗法免疫疗法纳米颗粒是一种纳米粒子.这是一个多ICIC.有针对性的癌症治疗.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.